NCT03715192View on ClinicalTrials.gov

A Safety Study of LY3462817 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

LY3462817 IV

Administered IV

BIOLOGICAL

LY3462817 SC

Administered SC

DRUG

Placebo

Administered IV

Trial Locations (1)

138623

Lilly Nus Centre for Clin Pharmacology, Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03715192 - A Safety Study of LY3462817 in Healthy Participants | Biotech Hunter | Biotech Hunter